8.22
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Adamas Pharmaceuticals Inc | ADMS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 8.22 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 8.22 | 8.22 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 8.22 | USD |
Period:
Draw Mode:
Adamas Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 376.37M | 45.79M | 40.85M | $ 74.46M | $ -52.84M | -2.02 | -4.80 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | 3.90% |
Adamas Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADMS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Month | 8.17 | 8.25 | 8.11 | 8.19 | 898,630 | 0.05 | 0.61% |
| 3 Months | 4.56 | 8.25 | 4.46 | 7.95 | 1,455,840 | 3.66 | 80.26% |
| 6 Months | 5.20 | 8.25 | 4.02 | 7.36 | 785,260 | 3.02 | 58.08% |
| 1 Year | 4.80 | 9.15 | 4.02 | 6.60 | 648,250 | 3.42 | 71.25% |
| 3 Years | 10.50 | 12.57 | 1.90 | 5.94 | 528,417 | -2.28 | -21.71% |
| 5 Years | 15.67 | 44.00 | 1.90 | 14.02 | 561,854 | -7.45 | -47.54% |
Adamas Pharmaceuticals Description
| Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States. |
